Government of Canada Provides Further Support to Proteocyte Diagnostics for Straticyte

Toronto, ON; November 21, 2016 – Proteocyte Diagnostics Inc. announced new support from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) for their novel prognostic oral cancer laboratory service. This continued support and technological advisory services will allow Proteocyte to add to their team to facilitate operations and Straticyte refinements. This support is timely as Straticyte™ was just featured at the American Association of Oral Maxillofacial Surgeons 98th Annual Meeting to over 4000 attendees including 1500 Oral Maxillofacial Surgeons.

Straticyte is a novel prognostic oral cancer laboratory service developed by Proteocyte Diagnostics. Used as a complement to conventional histopathology, it objectively and accurately detects oral lesions at high risk of transforming into cancer and those at low risk, giving oral and maxillofacial surgeons a tool they need to provide a better level of care. It can be easily incorporated into a clinical practice, since no additional tissue samples are needed for assessment.

The support from NRC-IRAP has been critical for Proteocyte Diagnostics to accelerate the automation of Straticyte, facilitate patent filings and refine the prediction algorithm for even greater accuracy. This investment ensures Proteocyte will be ready to process increased volumes from a larger geographical market while ensuring greater accuracy for oral pathologists and oral maxillofacial surgeons.

“We appreciate the support of NRC-IRAP,” said Mike Oliver, President and CEO of Proteocyte Diagnostics. “The funding means we can add to our product development team and be in a position to help patients across the globe quicker.”

About Proteocyte Diagnostics New website! Proteocyte Diagnostics is a Canadian company that has developed a novel prognostic oral precancer laboratory service, Straticyte™ that objectively and accurately detects oral lesions at high risk of transforming to cancer and those that pose low risk. Early diagnosis of high risk lesions permits more effective and less traumatizing treatments. By identifying and treating oral cancer before it happens, clinicians can save lives, healthcare costs are reduced and quality of life of patients is improved. Identifying more accurately low risk pre-cancerous lesions avoids unnecessary surgeries and allows clinicians to monitor patients regularly for peace of mind.

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Proteocyte management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.